Press release archive

July 24, 2014
FDA approves Flonase® Allergy relief for sale over-the-counter in the United States

July 24, 2014
GSK announces EU regulatory submission for malaria vaccine candidate RTS,S

July 23, 2014
Results announcement for the second quarter 2014

July 21, 2014
ViiV Healthcare presents phase III data comparing once-daily maraviroc in combination with darunavir/ritonavir with emtricitabine/tenofovir plus darunavir/ritonavir in treatment-naĂŻve adults with HIV-1

July 17, 2014
Trametinib (Mekinist™) and dabrafenib (Tafinlar™) combination demonstrated overall survival benefit compared to vemurafenib; phase III BRAF V600-mutant metastatic melanoma study stopped early

July 16, 2014
GSK begins shipping 2014-15 U.S. flu vaccines

July 15, 2014
GSK and Theravance announce initiation of phase III programme with fixed dose triple combination treatment FF/UMEC/VI in patients with COPD

July 09, 2014
Panadol® Advance 100 ct Product Recall in Puerto Rico

July 07, 2014
Matchmaking at GSK: highly skilled employees begin long-term PULSE volunteer assignments with nonprofit partners

July 04, 2014
GSK receives EU marketing authorisation for Mekinist (trametinib) for patients with unresectable or metastatic melanoma with a BRAF V600 mutation

July 03, 2014
Anoro Ellipta (umeclidinium/vilanterol) gains approval in Japan for the treatment of COPD

July 03, 2014
GSK and Genmab receive EU authorisation for Arzerra™ (ofatumumab) as first-line treatment for chronic lymphocytic leukaemia (CLL) in combination with chlorambucil or bendamustine for patients ineligible for fludarabine-based therapy

June 30, 2014
GSK and Theravance announce submission to US regulatory authorities for fluticasone furoate/vilanterol in asthma

June 30, 2014
GSK and Save the Children offer $1 million award for healthcare innovations in developing countries that reduce child deaths

June 27, 2014
GSK and Genmab announce top-line results from a Phase III study of ofatumumab versus physicians’ choice for bulky fludarabine-refractory CLL

June 27, 2014
Triumeq® (dolutegravir/abacavir/lamivudine) single-tablet regimen receives positive CHMP opinion in Europe for the treatment of HIV

June 25, 2014
GSK announces the start of a phase III study with eltrombopag in patients with myelodysplastic syndromes

June 24, 2014
GSK Statement: FDA Warning Letter - Ste-Foy Manufacturing Facility

June 14, 2014
GSK presents new data for once-weekly Tanzeum/Eperzan (albiglutide) showing blood glucose lowering up to three years in type 2 diabetes

June 13, 2014
GSK announces results of Phase III PETIT2 study of eltrombopag (Promacta/Revolade) in paediatric patients with chronic immune thrombocytopenia

June 12, 2014
ViiV Healthcare announces new collaboration with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

June 11, 2014
GSK and Theravance announce positive data from two studies evaluating the efficacy and safety of Incruse Ellipta when added to Relvar/Breo Ellipta in patients with COPD

June 5, 2014
GSK announces start of phase III cardiovascular outcomes study with losmapimod in patients with acute coronary syndrome

June 2, 2014
GSK, The Philadelphia Foundation Announce $5 Million Charitable Grant Program For a Healthier Philadelphia

May 23, 2014
GSK and Genmab receive CHMP positive opinion for Arzerra™ (ofatumumab) in combination with chlorambucil or bendamustine as a first-line treatment for patients with chronic lymphocytic leukaemia (CLL) who are not eligible for fludarabine-based therapy

May 23, 2014
GSK announces regulatory submission for umeclidinium monotherapy for COPD in Japan

May 20, 2014
GSK announces new commitment to improve access to vaccines with 5-year price freeze for countries graduating from GAVI Alliance support

May 19, 2014
GSK presents positive data at ATS 2014 from study evaluating efficacy and safety of Incruse™ Ellipta® added to Advair® Diskus® in patients with COPD

May 13, 2014
GSK announces phase III study with darapladib did not meet primary endpoint in patients following an acute coronary syndrome

May 08, 2014
Anoro (umeclidinium/vilanterol) gains marketing authorisation in Europe for the treatment of COPD

May 07, 2014
FDA approves Avandia (rosiglitazone) label update, lifts restrictions on patient access

May 06, 2014
GSK, Triangle Community Foundation Issue Call for Applications Totaling $400,000 in GSK IMPACT Awards

May 06, 2014
GSK, United Way of Greater Philadelphia and Southern New Jersey Issue Call for Applications Totaling $400,000 in GSK IMPACT Awards

April 30, 2014
GSK receives approval for Incruse™ Ellipta® (umeclidinium) in the US for the treatment of COPD

April 29, 2014
GSK announces start of phase III programme for mepolizumab in patients with COPD

April 28, 2014
GSK receives EU marketing authorisation for Incruse (umeclidinium) for the treatment of COPD

April 28, 2014
GSK and MMV announce start of phase III programme of tafenoquine for Plasmodium vivax malaria

April 25, 2014
GSK receives positive CHMP opinion for Mekinist™ (trametinib) in metastatic melanoma with a BRAF V600 mutation

April 23, 2014
Barnes Foundation Announces $500,000 Endowment Gift from GSK to Ensure Art Educational Experiences for Students from Philadelphia School District

April 22, 2014
GSK and Theravance announce phase III study of fluticasone furoate/vilanterol in COPD commenced to support potential future filing in Japan

April 22, 2014
GSK announces major 3-part transaction with Novartis to drive sustainable sales growth, improve long-term earnings and deliver increasing returns to shareholders

April 17, 2014
GSK and Genmab receive FDA approval for Arzerra® (ofatumumab) as first-line treatment in combination with chlorambucil for patients with Chronic Lymphocytic Leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate

April 17, 2014
GSK announces approval in Canada for Incruse Ellipta (umeclidinium) as a treatment for COPD

April 15, 2014
GSK receives US approval for once-weekly type 2 diabetes treatment, Tanzeum (TM) (albiglutide)

April 02, 2014
Update on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer

April 1, 2014
ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool

March 31, 2014
GSK announces new strategic investments in Africa to increase access to medicines, build capacity and deliver sustainable growth

March 30, 2014
GSK presents data from Phase III STABILITY study of darapladib in patients with chronic coronary heart disease

March 28, 2014
GSK acquires full ownership of its Indonesian Consumer Healthcare business

March 27, 2014
Where do you start when developing a new medicine?

March 26, 2014
GSK reports alli® product tampering, alerts consumers to unknown product in alli® packages

March 26, 2014
GSK receives European authorisation for once-weekly type 2 diabetes treatment, Eperzan® (albiglutide)

March 26, 2014
Regulatory update: combined use of Mekinist™ (trametinib) and Tafinlar® (dabrafenib) in Europe

March 20, 2014
Investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoints in MAGRIT, a phase III non-small cell lung cancer clinical trial

March 14, 2014
GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS® and ADVAIR® DISKUS® in patients with COPD

March 13, 2014
Introducing the Recipients of the $500,000 GSK IMPACT Grant for Denver

March 13, 2014
Patient recruitment completes in landmark RELVAR®/ BREO® ELLIPTA® Study to Understand Mortality and MorbidITy (SUMMIT) in COPD

March 12, 2014
GSK announces positive results from phase III studies for mepolizumab in severe eosinophilic asthma

March 09, 2014
GSK increases stake in Indian Pharmaceuticals subsidiary to 75 per cent after Open Offer

February 28, 2014
GSK announces submission to U.S. regulatory authorities for Promacta™ (eltrombopag) for severe aplastic anaemia

February 25, 2014
GSK kicks off 2014 Discovery Fast Track Challenge for academic drug hunters in Europe, Canada and US

February 20, 2014
Anoro® (umeclidinium / vilanterol) receives positive opinion from the CHMP in Europe for the treatment of COPD

February 20, 2014
GSK receives positive CHMP opinion for Incruse® (umeclidinium) for the treatment of COPD

February 4, 2014
The Acid Truth: Our Modern Diet Can Pose a Risk to Your Teeth

January 24, 2014
GSK announces headline results for Phase III study of the combination of Tafinlar® (dabrafenib) and Mekinist® (trametinib) in metastatic melanoma

January 24, 2014
GSK receives positive opinion from the CHMP in Europe for once-weekly EperzanTM (albiglutide) for the treatment of type 2 diabetes

January 13, 2014
Tafinlar® receives FDA Breakthrough Therapy designation for non-small cell lung cancer with BRAF mutation

January 13, 2014
Prosensa regains rights to drisapersen from GSK and retains rights to all other programmes for the treatment of Duchenne muscular dystrophy (DMD)

January 09, 2014
GSK gains accelerated FDA approval for combination use of Mekinist® (trametinib) and Tafinlar® (dabrafenib)

December 18, 2013
ANORO™ ELLIPTA™ approved as first once-daily dual bronchodilator for the treatment of COPD in the US

December 18, 2013
GSK announces $1 million innovation prize for bioelectronics research

December 17, 2013
GSK and Genmab Receive Priority Review from FDA for Arzerra® (ofatumumab) as 1st Line Treatment for Chronic Lymphocytic Leukaemia (CLL)

December 17, 2013
GSK announces changes to its global sales and marketing practices to further ensure patient interests come first

December 11, 2013
New England Journal of Medicine releases study showing GSK’s FluLaval Quadrivalent vaccine effective in preventing seasonal flu in children

December 6, 2013
GSK and Theravance announce positive results from pivotal phase III study for fluticasone furoate/vilanterol in asthma

December 5, 2013
GSK launches global consortium with six renowned cancer research centres

December 5, 2013
Synflorix™ receives European marketing authorisation for additional pneumonia indication

December 4, 2013
Nine innovative nonprofits receive $40,000 #GSKimpact Awards for contributing to a healthier Triangle region

November 28, 2013
Regulatory Update - GSK receives positive CHMP opinion for Cervarix™ two-dose schedule

November 25, 2013
GSK Responds to FDA Decision on Avandia (rosiglitazone)

November 20, 2013
GSK and Amicus Therapeutics announce revised Fabry agreement

November 20, 2013
Seven innovative nonprofits receive $40,000 GSK IMPACT Awards for contributing to a healthier Philadelphia

November 18, 2013
RELVAR® ELLIPTA® receives European marketing authorisation for the treatment of asthma and COPD

November 14, 2013
Five inspirational organisations from Malawi, Bangladesh, Mali, Kenya, and Colombia recognised by GSK and Save the Children

November 12, 2013
GSK announces top-line results from pivotal Phase III study of darapladib in chronic coronary heart disease

November 6, 2013
GSK names inaugural winners in unique competition for academic drug hunters

October 30, 2013
BREO® ELLIPTA™ now available in the U.S. for the treatment of COPD

October 29, 2013
New partnership between GSK and the Bill & Melinda Gates Foundation to accelerate research into vaccines for global health needs

October 29, 2013
GSK announces $500,000 charitable grant program for a healthier St. Louis

October 29, 2013
GSK announces $500,000 charitable grant program for a healthier Denver

October 25, 2013
Synflorix™ receives positive opinion from the CHMP in Europe for additional pneumonia indication

October 25, 2013
GSK to create a new Centre of Excellence for Sustainable Chemistry in Brazil

October 25, 2013
ViiV Healthcare announces European regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine for people living with HIV

October 23, 2013
Results announcement for the third quarter 2013

October 23, 2013
GSK announces US regulatory submission for fluticasone furoate monotherapy for asthma

October 18, 2013
Regulatory update – GSK and Genmab announce submission to US regulatory authorities for Arzerra® (ofatumumab) as 1st line treatment of Chronic Lymphocytic Leukaemia (CLL)

October 8, 2013
Malaria vaccine candidate reduces disease over 18 months of follow-up in late-stage study of more than 15,000 infants and young children

October 4, 2013
Regulatory update – GSK and Genmab announce European submission to regulatory authorities for Arzerra® (ofatumumab) as 1st line treatment of Chronic Lymphocytic Leukaemia (CLL)

September 30, 2013
GlaxoSmithKline reaches agreement with Aspen to divest thrombosis brands and related manufacturing site for ÂŁ0.7 billion

September 27, 2013
GSK and Barclays form partnership to increase access to healthcare and promote economic development in Zambia

September 24, 2013
GSK receives marketing authorisation from the European Commission for additional Revolade(TM) (eltrombopag) indication as the first approved treatment for chronic hepatitis C-associated thrombocytopenia

September 24, 2013
Information Notice on Certain Stolen Consumer Health Products from GlaxoSmithKline

September 19, 2013
RELVAR(TM) ELLIPTA(TM) receives positive opinion from the CHMP in Europe for the treatment of asthma and COPD

September 19, 2013
GSK signs a multi-year agreement with BARDA to supply the US government with anthrax treatment

September 18, 2013
GlaxoSmithKline, Community Care of North Carolina harness "small data" to improve patient care and reduce health care costs

September 13, 2013
FDA grants GSK and Genmab's Arzerra(R) (ofatumumab) Breakthrough Therapy designation for previously untreated chronic lymphocytic leukaemia

September 13, 2013
GSK statement in response to patent ruling reversal on Lovaza

September 12, 2013
GSK research estimates significantly higher rates of pertussis among older adults than now reported

September 10, 2013
FDA Advisory Committee recommends approval in US of umeclidinium/vilanterol for the treatment of COPD

August 23, 2013
GSK announces phase III study of vercirnon in patients with moderate-to-severe Crohn's disease did not meet its primary endpoint

August 16, 2013
Additional GlaxoSmithKline quadrivalent intramuscular flu vaccine approved by FDA

August 14, 2013
GSK receives marketing authorisation from the European Commission for additional indication: Tyverb™ (lapatinib) in combination with trastuzumab for patients with HER2-positive, HR-negative metastatic breast cancer

August 12, 2013
ViiV Healthcare announces U.S. approval of Tivicay® (dolutegravir) for the treatment of HIV-1

August 8, 2013
GSK launches $50 million venture capital fund to invest in pioneering bioelectronic medicines and technologies

August 7, 2013
GSK to discontinue manufacture and sale of the BEXXAR® therapeutic regimen (tositumomab and iodine I 131 tositumomab)

August 5, 2013
GlaxoSmithKline receives FDA approval to ship four-strain (quadrivalent) influenza vaccine to healthcare providers

August 2, 2013
GSK Announces Rollout of U.S.-Licensed Vaccines with 2D Barcodes

August 2, 2013
Regulatory update: albiglutide US PDUFA date extended by three months

July 29, 2013
GSK adds to its commitment to GAVI Alliance to help protect millions more children against infectious diseases

July 12, 2013
Regulatory update: fluticasone furoate / vilanterol submission in Japan

July 9, 2013
Regulatory Update - GSK announces US submission for dabrafenib/trametinib combination in metastatic melanoma

June 28, 2013
Regulatory Update - GSK receives positive CHMP opinions for Tafinlar® (dabrafenib) and Tyverb® (lapatinib)

June 27, 2013
GlaxoSmithKline’s drisapersen (previously GSK2402968/PRO051) to receive Food and Drug Administration Breakthrough Therapy designation for potential treatment of patients with Duchenne Muscular Dystrophy

June 27, 2013
GSK and Save the Children launch $1 million award to discover new healthcare innovations for reducing child deaths

June 26, 2013
100 GSK employees embark on global and local long-term volunteer assignments

June 24, 2013
GSK announces data from five Phase III studies of albiglutide, an investigational once-weekly treatment for type 2 diabetes

June 18, 2013
GSK receives offer for its thrombosis brands and related manufacturing site

June 06, 2013
GSK statement in response to FDA Advisory Committee’s vote on availability of Avandia (rosiglitazone)

June 01, 2013
GSK announces late-stage clinical data for VOTRIENT® (pazopanib) following chemotherapy in women with advanced epithelial ovarian cancer

May 30, 2013
National Survey Uncovers the Truth about Partial Dentures, Finds Few are Doing Enough to Ensure that their Partial Dentures are Always in Good Condition

May 29, 2013
Two new GSK oral oncology treatments, BRAF-inhibitor Tafinlar® (dabrafenib) capsules and the first MEK-inhibitor Mekinist™ (trametinib) tablets, approved by FDA as single-agent therapies

May 29, 2013
GSK and Genmab announce positive top-line results from pivotal trial of ARZERRA® (ofatumumab) combined with chlorambucil in previously untreated chronic lymphocytic leukaemia

May 23, 2013
GlaxoSmithKline and Impax Pharmaceuticals terminate their collaboration on IPX066

May 21, 2013
From novel research to innovative medicines: GSK launches Discovery Fast Track competition for academic researchers

May 10, 2013
BREO™ ELLIPTA™ gains US approval for the treatment of COPD

May 07, 2013
GSK gives update on plans to share detailed clinical trial data as part of its commitment to transparency

May 01, 2013
Regulatory update: Trametinib US PDUFA date extended to 3 September 2013

April 30, 2013
GSK announces regulatory submission for umeclidinium monotherapy in US

April 29, 2013
GlaxoSmithKline and Impax Pharmaceuticals terminate their collaboration on IPX066

April 22, 2013
GSK and Theravance announce regulatory submission for ANORO™ ELLIPTA™ (UMEC/VI) in Japan

April 17, 2013
FDA Advisory Committee recommends approval of BREO(TM) ELLIPTA(TM) for the treatment of COPD

April 17, 2013
GlaxoSmithKline, Triangle Community Foundation Issue Call for Applications Totaling $400,000 in GSK IMPACT Awards

April 17, 2013
GlaxoSmithKline Issues Call for Applications Totaling $400,000 in GSK IMPACT Awards

April 05, 2013
GlaxoSmithKline and Liberty Property Trust/Synterra Partners Transform the Work Environment with the Opening of Five Crescent Drive

April 03, 2013
GlaxoSmithKline announces start of phase III study of Benlysta® (belimumab ) in patients with vasculitis

March 26, 2013
Texas A&M System and GlaxoSmithKline receive U.S. Government approval to establish influenza vaccine facility in Texas

March 25, 2013
Regulatory Update: GlaxoSmithKline Receives Complete Response from FDA for Candidate Pandemic H5N1 Adjuvanted Influenza Vaccine

March 20, 2013
GSK publishes 2012 Corporate Responsibility report

March 18, 2013
$500,000 Endowment Gift from The GlaxoSmithKline Foundation Expands Program to Help Patients with Cancer and their Families at The Children’s Hospital of Philadelphia

March 07, 2013
Regulatory update – GSK announces regulatory submission for albiglutide in Europe

March 06, 2013
Americans Rate Themselves and Their Communities as Healthy, Despite Research Showing the Opposite

February 27, 2013
ViiV Healthcare announces a voluntary licence agreement with the Medicines Patent Pool to increase access to HIV medicines for children

February 19, 2013
GSK and Theravance announce FDA acceptance of New Drug Application (NDA) submission in the US for ANORO ELLIPTATM for COPD

February 06, 2013
Results announcement for the fourth quarter 2012

February 06, 2013
GlaxoSmithKline progresses multi-city discussion focused on improving the health of US communities

February 05, 2013
GSK announces support for AllTrials campaign for clinical trial transparency

February 05, 2013
GSK increases stake in its publicly-listed Consumer Healthcare subsidiary in India to 72.5 per cent

January 28, 2013
GSK and Biological E. announce joint venture to develop combination vaccine for India and other developing countries

January 24, 2013
GSK appoints Mr Hans Wijers to its Board as a Non-Executive Director

January 14, 2013
Regulatory update – GSK announces submission of albiglutide BLA to the US FDA for the treatment of type 2 diabetes

December 20, 2012
GlaxoSmithKline and Amicus Therapeutics announce top-line six-month primary treatment period results from first Phase III Fabry monotherapy study

December 19, 2012
GlaxoSmithKline and Amicus Therapeutics announce top-line six-month primary treatment period results from first Phase III Fabry monotherapy study

December 19, 2012
GlaxoSmithKline and Amicus Therapeutics announce top-line six-month primary treatment period results from first Phase III Fabry monotherapy study

December 17, 2012
FDA Approves GlaxoSmithKline’s four-strain seasonal influenza vaccine for use in the U.S. FDA Approves GlaxoSmithKline’s four-strain seasonal influenza vaccine for use in the U.S.

December 14, 2012
GSK receives FDA approval for raxibacumab anti-toxin for the treatment of inhalational anthrax

December 12, 2012
GlaxoSmithKline advances multi-city discussion focused on improving the health of US communities

December 10, 2012
GSK forms partnership with Vodafone to help increase childhood vaccination in Mozambique

November 28, 2012
GSK welcomes the publication of the 2012 Access to Medicines Index

November 26, 2012
GSK initiates voluntary open offer to increase stake in its publicly-listed Consumer Healthcare subsidiary in India

November 26, 2012
GSK announces agreement in principle to increase its stake in GlaxoSmithKline Consumer Nigeria PLC

November 19, 2012
FDA approves new indication for PROMACTA® (eltrombopag)

November 19, 2012
FDA approves new indication for PROMACTA® (eltrombopag)

November 14, 2012
GlaxoSmithKline announces vote from FDA advisory committee to recommend approval of H5N1 influenza vaccine candidate

November 09, 2012
RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants

November 08, 2012
GlaxoSmithKline honors healthcare nonprofits with $40,000 IMPACT Award

November 08, 2012
GlaxoSmithKline and XenoPort mutually agree to terminate their collaboration on Horizant

November 02, 2012
GSK announces FDA Advisory Committee vote in favour of raxibacumab for the treatment of inhalational anthrax infection

October 31, 2012
GSK supports BMJ commitment on clinical trial data transparency

October 31, 2012
Results announcement for the third quarter 2012

October 29, 2012
GSK announces start of Phase lll programme for mepolizumab in severe refractory asthma

October 29, 2012
Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio

October 24, 2012
GlaxoSmithKline Launches New Program to Help Consumers Recycle Empty GSK Respiratory Inhalers

October 22, 2012
Results from five phase III studies presented for GSK’s two candidate quadrivalent influenza vaccines

October 11, 2012
GSK announces further initiatives to advance openness and collaboration to help tackle global health challenges

October 09, 2012
Millions of children in Pakistan to be protected against pneumococcal disease with GSK’s Synflorix

October 04, 2012
Shionogi-ViiV Healthcare announces completion of initial clinical registration package for dolutegravir in HIV

October 01, 2012
Head-to-head study of GSK’s Votrient® (pazopanib) vs sunitinib in advanced renal cell carcinoma meets primary endpoint; findings presented at ESMO 2012 Congress

September 26, 2012
GlaxoSmithKline plc announces changes to its Board and Committees

September 26, 2012
GSK and Theravance announce FDA acceptance of FF/VI New Drug Application (NDA) submission in the US for COPD

September 24, 2012
GlaxoSmithKline initiates a multi-city conversation focused on improving the health of US communities

September 17, 2012
Regulatory Update: GSK announces submission for a new indication for Synflorix™ in Europe

September 13, 2012
GSK to acquire five million shares in Response Genetics for US$1.10 per share in cash

August 24, 2012
GSK and Theravance announce completion of the Phase III programme for once-daily LAMA/LABA (UMEC/VI) in COPD

August 23, 2012
GSK announces start of Phase III programme of sirukumab in rheumatoid arthritis

August 23, 2012
GSK announces start of Phase III programme of sirukumab in rheumatoid arthritis

August 15, 2012
GlaxoSmithKline reaches agreement to divest majority of Classic Brands in Australia for ÂŁ172m

August 08, 2012
GlaxoSmithKline and the American Lung Association join forces to help raise awareness of the impact of asthma in St. Louis

August 08, 2012
GlaxoSmithKline and the American Lung Association join forces to help raise awareness of the impact of asthma in St. Louis

August 03, 2012
GSK Completes Acquisition of Human Genome Sciences

August 03, 2012
Regulatory Update – GSK announces submissions in the EU and US for dabrafenib and trametinib

July 31, 2012
GlaxoSmithKline shipping U.S. flu vaccine with new strain coverage recommended for 2012-2013

July 31, 2012
GlaxoSmithKline shipping U.S. flu vaccine with new strain coverage recommended for 2012-2013

July 30, 2012
GSK announces acquisition of 79% of Human Genome Sciences shares; commences subsequent offering period

July 26, 2012
Once-daily dolutegravir is non-inferior to twice-daily raltegravir in treatment-naĂŻve adults with HIV-1

July 25, 2012
Results announcement for the second quarter 2012

July 17, 2012
GlaxoSmithKline and Amicus Therapeutics expand Fabry disease collaboration

July 16, 2012
GSK to acquire Human Genome Sciences for US$14.25 per share in cash

July 13, 2012
GSK and Theravance announce regulatory submissions for FF/VI in the US and Europe

July 12, 2012
US Regulatory Update – Tykerb® (lapatinib)

July 11, 2012
GSK announces positive data from Harmony 8 and completion of clinical registration package for albiglutide in type 2 diabetes

July 11, 2012
Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV

July 02, 2012
GlaxoSmithKline concludes previously announced agreement in principle to resolve multiple investigations with US Government and numerous states

July 02, 2012
GSK and Theravance announce positive results from four pivotal phase III studies for once-daily LAMA/LABA (UMEC/VI) in COPD

June 29, 2012
GSK sets 20 July for expiration of tender offer to acquire Human Genome Sciences

June 27, 2012
GlaxoSmithKline Employees Embark on Long-Term Volunteer Assignments throughout the World

June 18, 2012
Supreme Court rules sales reps exempt from overtime payments under outside sales exemption of Fair Labor Standards Act

June 15, 2012
Stiefel Signs Worldwide Acquisition and License Agreement for alitretinoin

June 15, 2012
GSK continues with tender offer to acquire all outstanding shares of Human Genome Sciences

June 14, 2012
GSK receives FDA approval for MenHibrix

June 09, 2012
GSK announces new 52-week data from phase III study of once-weekly albiglutide in type 2 diabetes

June 08, 2012
GSK extends tender offer for all outstanding shares of Human Genome Sciences

June 07, 2012
GSK and XenoPort receive FDA approval for Horizant® for postherpetic neuralgia

June 04, 2012
GSK presents positive results for investigational BRAF and MEK inhibitors dabrafenib and trametinib at ASCO

June 01, 2012
GSK announces expiration of Hart-Scott-Rodino waiting period for tender offer for HGS

May 30, 2012
Regulatory Update – GSK announces submissions in the EU & US for new indications for Promacta®/Revolade®

May 29, 2012
GlaxoSmithKline confirms US District Court ruling in Pronova BioPharma’s favour on Lovaza™ patents

May 29, 2012
GSK announces start of Phase III programme for combination of dabrafenib (GSK2118436) and trametinib (GSK1120212) in BRAF V600 mutation-positive metastatic cutaneous melanoma

May 25, 2012
GSK receives positive opinion from European CHMP for pazopanib in the treatment of patients with certain advanced soft tissue sarcomas

May 24, 2012
Innovative public-private collaboration launches to tackle antibiotic research

May 21, 2012
Auxilium Pharmaceuticals, Inc. and GlaxoSmithKline LLC enter into a co-promotion agreement for TESTIM® in the U.S.

May 17, 2012
GSK statement on tender offer to acquire Human Genome Sciences

May 16, 2012
GlaxoSmithKline completes transaction to increase its ownership in Theravance

May 15, 2012
GlaxoSmithKline to fully acquire Cellzome for ÂŁ61 million

May 11, 2012
Stiefel receives US FDA approval of Fabior™ Foam, 0.1%

May 10, 2012
GSK commences tender offer to acquire Human Genome Sciences for US $13.00 per share in cash

May 09, 2012
GSK to commence tender offer to acquire Human Genome Sciences for US $13.00 per share in cash

May 03, 2012
GlaxoSmithKline plc appoints two Non-Executive Directors to its Board

May 01, 2012
GlaxoSmithKline and Yale University establish drug discovery collaboration to design potential new class of medicines

April 27, 2012
Mayor Nutter Announces $1 Million Grant from GSK and The Philadelphia Foundation for Summer Youth Internships

April 26, 2012
FDA approves Votrient® for treatment of patients with certain types of advanced soft tissue sarcoma

April 26, 2012
GSK and University of Nottingham collaborate to create Centre of Excellence for sustainable chemistry

April 25, 2012
Results announcement for the first quarter 2012

April 20, 2012
GlaxoSmithKline reaches agreement to divest non-core over-the-counter (OTC) brands in international markets for ÂŁ164 million

April 19, 2012
GlaxoSmithKline’s Science in the Summer Partners with The Franklin Institute to Bring Free Hands-On Science to Elementary Students at Philadelphia-area Libraries

April 11, 2012
GSK provides update on corporate responsibility commitments in 2011 report

April 04, 2012
GlaxoSmithKline named a Member of America’s Health Insurance Plans (AHIP) 2012 Select Program

April 03, 2012
GSK receives further data from phase lll studies of albiglutide in type 2 diabetes

April 02, 2012
GlaxoSmithKline to increase its ownership in Theravance

April 02, 2012
Shionogi-ViiV Healthcare announces initial data from pivotal phase III study of dolutegravir in HIV

March 26, 2012
GSK and Genentech Reach Patent Settlement

March 23, 2012
GSK and Theravance announce completion of the Relovair™* registrational programme and topline results from Relovair™ vs. Advair® phase III studies in COPD

March 20, 2012
GSK announces positive vote from FDA panel for pazopanib in certain advanced soft tissue sarcomas

March 20, 2012
New survey reveals lupus communication gap as many patients remain silent on true impact of disease

March 15, 2012
GlaxoSmithKline provides further update on divestment of non-core over-the-counter (OTC) brands

March 08, 2012
GlaxoSmithKline, Triangle Community Foundation Invite Healthcare Nonprofits to Apply for $40,000 IMPACT Awards

March 06, 2012
GlaxoSmithKline Invites Philadelphia Area and City of Camden Healthcare Nonprofits to Apply for $40,000 IMPACT Awards

March 05, 2012
Regulatory Update: GSK announces submissions for two influenza vaccines

March 01, 2012
GSK and Daiichi Sankyo vaccines joint venture to become largest vaccines company in Japan

February 17, 2012
GlaxoSmithKline receives positive opinion in Europe from the CHMP for Nimenrix®

February 16, 2012
EU and US Regulatory Update – Tykerb/Tyverb® (lapatinib)

February 07, 2012
GSK results announcement for Q4 and full year 2011

January 30, 2012
GSK joins new global partnership to help defeat ten neglected tropical diseases by 2020

January 27, 2012
GSK announces changes to the Board

January 19, 2012
New Press Release Publishing System launched for us.gsk.com

January 09, 2012
GSK and Theravance announce initial outcomes from pivotal Phase III studies for once-daily RelovairTM* in COPD and asthma

December 20, 2011
GlaxoSmithKline provides update on divestment of non-core over-the-counter (OTC) brands

December 16, 2011
GSK extends pneumococcal vaccine agreement with GAVI Alliance

December 15, 2011
GlaxoSmithKline and Human Genome Sciences initiate phase III trial of belimumab (Benlysta®) administered subcutaneously in subjects with systemic lupus erythematosus

December 08, 2011
GSK presents phase lll data for lapatinib at San Antonio breast cancer symposium

December 06, 2011
GSK announces changes to the REMS program for PROMACTA® (eltrombopag)

December 01, 2011
Regulatory Update: GlaxoSmithKline submits additional information for candidate meningococcal and Hib combination vaccine

December 01, 2011
Reporting on a core earnings basis will begin with effect from Q1 2012

November 17, 2011
GSK welcomes GAVI Alliance decision to introduce vaccines against cervical cancer and rubella in the world’s poorest countries

November 17, 2011
GlaxoSmithKline welcomes innovative knowledge-sharing collaboration to break deadlock in antibiotic discovery and development

November 16, 2011
GSK receives initial data from the first completed phase lll study of albiglutide in type 2 diabetes

November 09, 2011
Data published in The Lancet Oncology support high efficacy previously demonstrated by Cervarix® (HPV 16 and 18 vaccine) against precancerous cervical lesions caused by HPV 16 and 18 and also efficacy against certain other cancer-causing HPV types

November 07, 2011
GSK presents phase III results for eltrombopag in hepatitis C virus related thrombocytopenia

November 03, 2011
GlaxoSmithKline reaches agreement in principle to resolve multiple investigations with US Government

October 26, 2011
GSK delivers strong Q3 performance with underlying sales growth of 6% and reported sales growth of 3%

October 26, 2011
GSK joins WIPO Re:Search open innovation platform as part of its commitment to tackling diseases of the developing world

October 18, 2011
First results from ongoing Phase III trial show malaria vaccine candidate, RTS,S* reduces the risk of malaria by half in African children aged 5 to 17 months

September 23, 2011
Regulatory Update: GlaxoSmithKline receives Complete Response letter from FDA for candidate meningococcal and Hib combination vaccine

September 15, 2011
GlaxoSmithKline (GSK) and McLaren Group announce innovative strategic partnership

September 13, 2011
GlaxoSmithKline (GSK) commits $1 million in cervical cancer vaccine to new cooperative effort aimed at reducing deaths from women's cancers

September 12, 2011
GlaxoSmithKline and Amicus Therapeutics commence second phase III study of Amigal™ for Fabry disease

September 12, 2011
GSK gives update on agreement with World Health Organization to support de-worming of school age children in endemic countries

September 09, 2011
Lapatinib clinical trial update

September 07, 2011
Jens Eckstein named President of SR One, GSK’s venture healthcare group

September 06, 2011
GSK awarded contract by BARDA to support research on potential novel antibiotic

August 29, 2011
GlaxoSmithKline joins North Carolina employer coalition to offer medical homes

August 22, 2011
GSK takes minority stake in new spin out Autifony Therapeutics

August 15, 2011
GSK and Impax announce positive topline results of ASCEND-PD Phase III study of IPX066 in Advanced Parkinson’s disease

August 10, 2011
GSK and Enigma Diagnostics announce collaboration on assay development and commercialisation of Enigma’s ML platform

August 09, 2011
Regulatory Update: GSK and XenoPort submit supplemental New Drug Application to FDA for Horizant™ in postherpetic neuralgia

August 03, 2011
Regulatory update – Stiefel, a GSK company, files NDA for tazarotene foam

July 26, 2011
GSK delivers strong Q2 performance with underlying sales growth* of 5%, increased pipeline visibility and dividend of 16p, up 7%

July 21, 2011
GlaxoSmithKline European regulatory update on Pandemrix™

July 18, 2011
GlaxoSmithKline pledges $10 million at White House meeting on US education reform

July 15, 2011
GlaxoSmithKline begins distribution of flu vaccine to U.S. customers for 2011-2012 flu season

July 14, 2011
GlaxoSmithKline and Human Genome Sciences receive European authorisation for Benlysta® (belimumab)

July 08, 2011
GlaxoSmithKline receives FDA approval for BOOSTRIX to help prevent whooping cough in adults 65 years and older

July 06, 2011
EU and US Regulatory Update - Votrient® (pazopanib)

July 05, 2011
GlaxoSmithKline implements next phase of new incentive compensation program for U.S. sales representatives

July 04, 2011
London 2012 partner, GlaxoSmithKline, shares scientific expertise with World Anti-Doping Agency to help fight against abuse of drugs in sport

July 01, 2011
GlaxoSmithKline receives new approval for Rotarix and significant new indication for Lamictal® (lamotrigine) in Japan

June 28, 2011
media contacts testing

June 28, 2011
GSK welcomes external scientists to diseases of the developing world research campus

June 24, 2011
GSK statement on University of East Anglia study examining health impacts of anticholinergic medicines for over 65s

June 23, 2011
GSK statement on agreements with State Attorneys General on former Cidra manufacturing facility

June 14, 2011
GSK to purchase Shenzhen Neptunus stake in previously formed joint venture for influenza vaccines in China

June 13, 2011
GlaxoSmithKline and Valeant announce US FDA approval of Potiga™ (ezogabine)

June 09, 2011
GlaxoSmithKline & Liberty/Synterra break ground on Five Crescent Drive at The Philadelphia Navy Yard

June 06, 2011
Millions of children in the world’s poorest countries could receive vaccination against rotavirus diarrhoeal disease under new offer made by GSK to the GAVI Alliance

June 04, 2011
GlaxoSmithKline’s pazopanib improved progression free survival in adults with certain soft tissue sarcomas

June 02, 2011
GSK and Theravance announce results of two pivotal Phase III studies for Relovair in COPD

May 24, 2011
GSK forms partnership with three leading NGOs to address shortage of frontline healthcare workers in Least Developed Countries (LDCs)

May 20, 2011
GlaxoSmithKline and Human Genome Sciences receive positive opinion in Europe from the CHMP for Benlysta® (belimumab)

May 19, 2011
GlaxoSmithKline Drug Development seeks more insight into Hispanic health care needs

April 27, 2011
GSK Q1 performance demonstrates continued progress with delivery of underlying sales growth, cash generation and pipeline visibility

April 27, 2011
usgskcom test

April 25, 2011
FDA approves Lamictal®XR™(lamotrigine) for conversion to monotherapy for treatment of partial seizures in appropriate patients

April 21, 2011
New survey finds gap in doctor-patient migraine communication

April 18, 2011
Regulatory update – GSK and Valeant respond to FDA on ezogabine

April 18, 2011
GSK welcomes key agreement to support global preparedness against pandemic influenza

April 15, 2011
Regulatory Update: GlaxoSmithKline submits additional information for candidate meningococcal and Hib combination vaccine

April 15, 2011
Regulatory Update - Tyverb® (lapatinib)

April 15, 2011
Regulatory Update - Tyverb® (lapatinib)

April 14, 2011
GlaxoSmithKline announces non-core OTC products to be divested

April 12, 2011
Unique research alliance expands collaboration opportunities at state-of-the-art medical imaging centre

April 11, 2011
New Press Release Publishing System will be launching for us.gsk.com

April 06, 2011
GlaxoSmithKline and XenoPort receive FDA approval for Horizant™

April 01, 2011
New Press Release Publishing System will be launching for us.gsk.com

March 31, 2011
GSK publishes payments for research, consulting and advising by US healthcare professionals

March 30, 2011
GlaxoSmithKline confirms Pronova BioPharma reaches agreement with Apotex regarding Lovaza™ US patent litigation

March 28, 2011
GSK publishes 2010 Corporate Responsibility Report

March 24, 2011
GlaxoSmithKline Pledges $5 Million Grant to City of Philadelphia for Youth Development

March 23, 2011
GSK statement on Avodart™ (dutasteride) for prostate cancer risk reduction

March 18, 2011
GSK supports recovery efforts to help those affected by the Tohoku Kanto earthquake

March 11, 2011
GlaxoSmithKline and Tolerx announce phase III DEFEND-1 study of otelixizumab in type 1 diabetes did not meet its primary endpoint

March 10, 2011
GSK’s anti-epileptic drug Lamictal® XR™ (lamotrigine) reviewed by FDA advisory committee

March 10, 2011
GlaxoSmithKline establishes dedicated team to support community pharmacists

March 09, 2011
GlaxoSmithKline and Human Genome Sciences announce FDA approval of Benlysta® (belimumab) for the treatment of systemic lupus erythematosus

March 04, 2011
GlaxoSmithKline plc appoints two Non-Executive Directors to its Board

February 25, 2011
FDA grants full approval for PROMACTA® (eltrombopag) for treatment of rare blood disorder

February 25, 2011
David Redfern appointed as new Chairman of ViiV Healthcare

February 16, 2011
GlaxoSmithKline 15th Annual IMPACT Awards seek Philadelphia area and Camden healthcare nonprofits

February 11, 2011
First African country introduces GSK’s pneumococcal vaccine through innovative financing mechanism

February 08, 2011
GlaxoSmithKline moving to new building at Philadelphia Navy Yard

February 07, 2011
GSK revises US Avandia label to include new restrictions on use

February 07, 2011
GlaxoSmithKline and Human Genome Sciences announce publication of BLISS-52 phase lll study results for Benlysta® in The Lancet

February 03, 2011
GSK results announcement for the fourth quarter

February 03, 2011
GSK and Theravance announce progression of LAMA/LABA combination treatment into Phase III development for COPD

February 01, 2011
GSK announces the sale of its entire shareholding in Quest Diagnostics

January 28, 2011
GSK and Actelion discontinue clinical development of almorexant

January 26, 2011
GSK receives FDA Complete Response letter for Avodart for prostate cancer risk reduction supplemental indication

January 24, 2011
Important information for ARIXTRA® Starter Kit patients regarding Triad Group’s alcohol prep products

January 24, 2011
GlaxoSmithKline announces start of two phase III studies in advanced/metastatic melanoma

January 21, 2011
Regulatory update - GSK and Valeant receive positive opinion in Europe from the CHMP for Trobalt (retigabine)

January 19, 2011
GSK and Prosensa announce start of Phase III study of investigational Duchenne Muscular Dystrophy medication

January 19, 2011
GlaxoSmithKline commences Phase III study of intravenous zanamivir for hospitalised patients with influenza

January 17, 2011
GlaxoSmithKline announces Q4 2010 legal charge

January 14, 2011
Information Notice on Stolen Consumer Health Products from GlaxoSmithKline

January 12, 2011
GlaxoSmithKline and ChemoCentryx announce initiation of Phase III study of GSK’786, formerly Traficet-EN™, for the treatment of Crohn’s disease

January 10, 2011
HealthCoach4Me, GlaxoSmithKline’s new, virtual health-coaching Website helps consumers reach health and wellness goals

January 07, 2011
GlaxoSmithKline and DENTSPLY International sign global agreement to create a portfolio of co-branded professional oral care products

January 02, 2011
GSK responds to 60 Minutes

[an error occurred while processing this directive]

December 21, 2010
GlaxoSmithKline and Theravance commence MABA Phase IIb COPD study

December 20, 2010
GSK appoints PHD to manage all US media planning and buying

December 16, 2010
GlaxoSmithKline and Impax Pharmaceuticals enter global agreement to develop and commercialise a late stage compound for Parkinson’s Disease

December 16, 2010
Andrew Witty appointed Lead Non-Executive Board Member for the Department for Business, Innovation and Skills (BIS)

December 13, 2010
GSK to strengthen Nutritional Healthcare business with acquisition of Maxinutrition

December 10, 2010
Phase III study in HER2-positive advanced breast cancer shows overall survival benefit when Tykerb is combined with paclitaxel

December 10, 2010
Data from Tykerb investigational phase III studies in neo-adjuvant HER2-positive breast cancer presented at breast cancer symposium

December 07, 2010
GSK signs agreement to acquire Nanjing MeiRui Pharmaceuticals in China

December 03, 2010
GlaxoSmithKline and Human Genome Sciences announce FDA extension of Benlysta® PDUFA target date to 10th March 2011

December 01, 2010
Avodart reviewed by FDA advisory committee for prostate cancer risk reduction

December 01, 2010
GSK and Valeant announce receipt of U.S. FDA Complete Response letter for ezogabine

November 29, 2010
Government patent box proposals ‘transform’ UK attractiveness for investment

November 29, 2010
GlaxoSmithKline to increase its shareholding in Theravance

November 26, 2010
GlaxoSmithKline and JSC Binnopharm enter vaccine production alliance in Russia

November 23, 2010
GlaxoSmithKline and Dr Reddy’s agree to the sale of US penicillin facility and products

November 22, 2010
GSK statement on dismissal of Paxil product liability trial in Philadelphia Court of Common pleas

November 17, 2010
COPD patients reveal disease progression leads to physical and social isolation and increased reliance on the internet

November 16, 2010
Human Genome Sciences and GlaxoSmithKline announce vote of FDA advisory committee to recommend approval of Benlysta® for systemic lupus erythematosus

November 15, 2010
New study findings show no benefit of prescription omega-3 fatty acids in prevention of recurrent symptomatic atrial fibrillation in affected patients

November 12, 2010
GlaxoSmithKline and Fiocruz extend innovative collaboration to research and develop new medicines for neglected tropical diseases

November 05, 2010
GlaxoSmithKline and XenoPort respond to FDA on Horizant™ for RLS

November 05, 2010
GlaxoSmithKline and XenoPort respond to FDA on Horizant™ for RLS

November 05, 2010
GlaxoSmithKline and XenoPort respond to FDA on Horizant™ for RLS

October 29, 2010
GlaxoSmithKline receives approval in Japan for two medicines: Revolade and Xyzal

October 29, 2010
GSK and Amicus Therapeutics enter exclusive worldwide agreement to develop and commercialise Amigal™ for Fabry disease

October 28, 2010
GlaxoSmithKline Consumer Healthcare Begins Installation of North America’s Largest Rooftop Solar Array

October 26, 2010
xxxxxxxxxxxxxxxxxxxxxxxxxx

October 26, 2010
xxxxxxxx

October 26, 2010
xxxxxxxxxxxxxxxxxxxxxxxx

October 26, 2010
xxxxxxxxxxxxxxxxxxxxxxxx

October 26, 2010
xxxxxxxxxxxxxxxxxx

October 26, 2010
GSK completes previously reported settlement with U.S. Department of Justice regarding former manufacturing plant

October 26, 2010
GSK completes previously reported settlement with U.S. Department of Justice regarding former manufacturing plant

October 22, 2010
CorePharma and GlaxoSmithKline conclude agreement on US rights for Dexedrine®, Albenza® and Daraprim®

October 21, 2010
GSK announces Q3 results for 2010

October 18, 2010
GSK outlines approach to delivering advances in the treatment of rare diseases

October 18, 2010
GSK, Fondazione Telethon and Fondazione San Raffaele to collaborate on gene therapy for rare diseases

October 14, 2010
GSK increases support for WHO strategy to improve children’s health with new 5-year commitment to expand donations of albendazole medicine

October 12, 2010
Stiefel, a GSK company, receives FDA approval of SORILUX™ (calcipotriene) Foam, 0.005%

October 04, 2010
GSK takes minority stake in newly formed Convergence Pharmaceuticals

October 01, 2010
GSK maintains perfect score for corporate equality from Human Rights Campaign

September 30, 2010
A Statement from GlaxoSmithKline Consumer Healthcare on FDA Regulation of Smokeless Tobacco Products

September 30, 2010
GSK provides update on Herpevac trial for women evaluating Simplirix™ (Herpes Simplex Vaccine)

September 30, 2010
A Statement from GlaxoSmithKline Consumer Healthcare on FDA Regulation of Smokeless Tobacco Products

September 30, 2010
A Statement from GlaxoSmithKline Consumer Healthcare on

September 29, 2010
Soccer champion Mia Hamm teams with GSK to encourage adults to “Give Your Health A Shot”

September 23, 2010
GSK regulatory update on Avandia following EMA and FDA reviews

September 22, 2010
GSK and Theravance announce combination ICS/LABA Phase II results in the Relovair™ development programme

September 16, 2010
GlaxoSmithKline and Genmab refocus development programme for ofatumumab in autoimmune indications

September 15, 2010
Three-year results from ECLIPSE study indicate that COPD patients may require prevention strategies to manage exacerbations, regardless of disease severity

September 11, 2010
GSK and BJD collaborate on a new educational programme to reduce global burden of joint pain

September 11, 2010
BJD and GSK collaborate on a new educational programme to reduce global burden of joint pain

September 08, 2010
GlaxoSmithKline and Genmab announce start of ofatumumab Phase III combination study in non-Hodgkin’s lymphoma

September 08, 2010
GSK announces succession plan for Chief Financial Officer

September 08, 2010
Galapagos reaches agreement to acquire GlaxoSmithKline research centre in Zagreb, Croatia

September 08, 2010
GSK signs agreement with Lonza to secure capacity and expertise in biological manufacturing to support ongoing development of GSK’s biopharmaceuticals portfolio

September 06, 2010
GlaxoSmithKline responds to British Medical Journal article regarding Avandia® (rosiglitazone)

August 30, 2010
GSK and Valeant announce new U.S. FDA PDUFA goal date for ezogabine

August 23, 2010
GSK commences Phase III clinical trials to develop herpes zoster vaccine for the prevention of shingles

August 19, 2010
GlaxoSmithKline and Human Genome Sciences announce FDA priority review designation for Benlysta® (belimumab) as a potential treatment for systemic lupus erythematosus

August 18, 2010
Test content

August 11, 2010
Ezogabine, an investigational anti-epileptic drug, receives positive vote from FDA advisory committee

August 09, 2010
GSK and Genmab announce topline results from the concluded pivotal trial of Arzerra (ofatumumab) in fludarabine and alemtuzumab refractory chronic lymphocytic leukemia

August 05, 2010
Image of new antibiotic in action opens up new opportunities to combat antibacterial resistance

July 30, 2010
GlaxoSmithKline begins distribution of flu vaccine to U.S. customers for 2010-2011 flu season

July 29, 2010
GSK exercises option on Anacor’s novel antibiotic for the treatment of gram-negative infections

July 26, 2010
GlaxoSmithKline to Implement New Compensation Program for U.S. Sales Professionals

July 26, 2010
GlaxoSmithKline to Implement New Compensation Program for U.S. Sales Professionals

July 26, 2010
GlaxoSmithKline to Implement New Compensation Program for U.S. Sales Professionals

July 21, 2010
GlaxoSmithKline statement in response to FDA announcement on TIDE trial

July 21, 2010
GSK announces Q2 results for 2010

July 19, 2010
Testing SCS Target

July 16, 2010
GlaxoSmithKline and Genmab announce amendment to Ofatumumab agreement

July 16, 2010
Update to 2009 Notification of Stolen Advair Diskus Inhalers

July 16, 2010
Stiefel, a GSK company, Receives FDA Approval of VELTIN™ (clindamycin phosphate and tretinoin) Gel 1.2%/0.025%

July 15, 2010
GlaxoSmithKline legal update

July 14, 2010
GlaxoSmithKline statement in response to FDA Advisory Committees’ vote on safety of Avandia® (rosiglitazone)

July 14, 2010
Information Notice on Certain Stolen Consumer Health Products from GlaxoSmithKline

July 13, 2010
GlaxoSmithKline (GSK) responds to Senate Finance Committee letter of 12 July to FDA

July 09, 2010
Data support Avandia (rosiglitazone maleate) cardiovascular safety profile

July 07, 2010
GlaxoSmithKline and XenoPort report top-line phase 2b results for GSK1838262/XP13512 as a prophylactic treatment for migraine headache

July 02, 2010
GSK and EDB commit $35 million (USD) in funding to support research in green and sustainable manufacturing in Singapore

July 02, 2010
Pandemic (H1N1) 2009 Influenza Update: GSK’s H1N1 ‘Pandemrix’ vaccine receives positive opinion from European Regulators

July 01, 2010
Test

July 01, 2010
BC and Goody’s online “Pick A Powder” contest kicks off starring Trace Adkins and Richard Petty

July 01, 2010
GSK and Aptuit finalise agreement for Aptuit to acquire GSK’s research operations in Italy

June 23, 2010
GlaxoSmithKline enters agreement with Medivir for exclusive rights to cold sore treatment Xerclear™

June 18, 2010
FDA approves STAXYN™ (vardenafil HCl) orally disintegrating tablets for erectile dysfunction (ED)

June 14, 2010
FDA approves Jalyn™, a fixed-dose combination of dutasteride and tamsulosin, for symptomatic BPH in men with an enlarged prostate

June 11, 2010
GlaxoSmithKline Receives Complete Response from FDA for Candidate Meningococcal and Hib Combination Vaccine

June 11, 2010
GlaxoSmithKline Receives Complete Response from FDA for Candidate Meningococcal and Hib Combination Vaccine

June 10, 2010
GSK drives Latin America growth strategy with acquisition of Laboratorios Phoenix

June 10, 2010
Regulatory update – BLA filed for Benlysta® (belimumab)

June 02, 2010
GSK announces revised product labels for Serevent and Advair

June 02, 2010
GSK announces revised product labels for Serevent and Advair

May 26, 2010
GSK Consumer Healthcare to update alli label as FDA completes safety review of orlistat

May 19, 2010
New research identifies promising leads to follow in search for medicines to fight malaria

May 14, 2010
FDA says Healthcare Providers can resume use of Rotarix (Rotavirus Vaccine, Live, Oral)

May 11, 2010
Patrick Vallance appointed to GSK executive leadership team

May 11, 2010
GSK extends presence in Asia with new strategic alliance in South Korea

May 07, 2010
GSK Statement on FDA Advisory Committee Meeting on Rotavirus Vaccines

May 04, 2010
New survey shows families may not be addressing their oral health care needs

May 01, 2010
Test Press Release

April 28, 2010
GSK announces Q1 results for 2010

April 27, 2010
New Nicorette mini lozenge offers convenient, pocket-sized support to help smokers looking to quit

April 20, 2010
GlaxoSmithKline and Human Genome Sciences announce topline 76-week results of phase 3 trial of Benlysta™ in systemic lupus erythematosus

April 13, 2010
GlaxoSmithKline honors healthcare nonprofits with $360,000 in awards

March 31, 2010
GSK and Isis Pharmaceuticals collaborate on RNA therapeutics for rare and infectious diseases

March 29, 2010
GSK regulatory update – Avodart (dutasteride)

March 29, 2010
GSK offers free vaccines to uninsured adults

March 26, 2010
Updated GlaxoSmithKline statement on European regulatory guidance relating to manufacture of Rotarix (rotavirus vaccine)

March 23, 2010
GSK responds to JAMA editorial and commentary

March 23, 2010
GSK responds to JAMA editorial and commentary

March 23, 2010
GSK joins global vaccine alliance to help prevent millions of children from contracting pneumococcal disease in the world’s poorest countries

March 22, 2010
GlaxoSmithKline statement on new information relating to manufacture of Rotarix (rotavirus vaccine)

March 22, 2010
GSK announces succession plan for leadership of Consumer Healthcare business

March 19, 2010
GlaxoSmithKline commences Relovair Phase III asthma programme

March 16, 2010
GSK publishes 2009 Corporate Responsibility Report

March 15, 2010
Reminder: GlaxoSmithKline 14th Annual IMPACT awards application deadline March 29, 2010

March 12, 2010
GSK commences succession plan for management of vaccines business

March 08, 2010
GSK CEO Andrew Witty dedicates albendazole facility in Nashik to WHO’s Global Programme to Eliminate LF

February 24, 2010
GlaxoSmithKline responds to US Senate Committee on Finance report on Avandia

February 24, 2010
GlaxoSmithKline responds to US Senate Committee on Finance report on Avandia

February 24, 2010
Information notice on certain stolen pharmaceutical and consumer health products from GlaxoSmithKline

February 24, 2010
Information notice on certain stolen pharmaceutical and consumer health products from GlaxoSmithKline

February 20, 2010
GSK rejects conclusions of Senate Committee on Finance Staff Report on Avandia

February 20, 2010
GSK rejects conclusions reported in The New York Times story on Avandia

February 20, 2010
GSK rejects conclusions reported in The New York Times story on Avandia

February 18, 2010
GSK statement on FDA’s proposed label revisions for some asthma medicines

February 18, 2010
GSK Consumer Healthcare warns consumers of potential health risks associated with long-term excessive use of zinc-containing denture adhesives

February 17, 2010
GlaxoSmithKline and XenoPort receive FDA Complete Response letter for Horizant™ (GSK1838262/XP13512) for RLS

February 15, 2010
GlaxoSmithKline 14th Annual IMPACT Awards seek Greater Philadelphia and Camden healthcare nonprofits

February 10, 2010
GlaxoSmithKline introduces CARES by GSK to improve patient access to GSK oncology and specialty medicines

February 04, 2010
GSK launches new specialist unit to research and develop medicines for rare diseases

February 04, 2010
GSK announces appointment of Philippe Fauchet as President of GSK Japan

February 04, 2010
Results announcement for the fourth quarter 2009

February 02, 2010
tes

February 02, 2010
Make the big game healthy and heartburn free

January 29, 2010
GSK’s TYKERB receives accelerated approval for first-line combination treatment of metastatic breast cancer

January 29, 2010
FDA approves once-a-day LamictalXR as add-on epilepsy therapy for primary generalized tonic-clonic seizures

January 26, 2010
GlaxoSmithKline grants $360,000 to nine healthcare nonprofits – each to receive $40,000

January 20, 2010
GSK announces ‘open innovation’ strategy to help deliver new and better medicines for people living in the world’s poorest countries

January 18, 2010
GSK contributes to Haiti relief efforts

January 15, 2010
GlaxoSmithKline update: Government orders for pandemic H1N1 vaccine

January 15, 2010
GlaxoSmithKline update: Government orders for pandemic H1N1 vaccine

January 13, 2010
Eight in 10 Americans say they’re in control of their eating habits – but growing obesity crisis tells another story

January 12, 2010
GlaxoSmithKline update: Government orders for pandemic H1N1 vaccine

January 11, 2010
GSK exercises option to progress development of ChemoCentryx’s Traficet-EN for the treatment of inflammatory bowel diseases

January 05, 2010
This is for testing us press release-2010

[an error occurred while processing this directive] [an error occurred while processing this directive]


This section contains information in several formats:

To download PDF files you will need Adobe Reader. If you do not have it installed, it is available free from the Adobe website. PDF links on this site open in a new window.

For audio-visual content you can use either Windows Media Player or Real Player, which can be installed free from their respective websites.